Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // June 22nd, 2011 // 6:43 am
Top of the morning to you. Another busy day here on the Pharmalot corporate campus, where we continue our own version of R&D - you know, reading documents and learning interesting tidbits - amid meetings and deadlines. We trust you can relate. So please join us for that mandatory cup or three of stimulation. What would do without them? Meanwhile, here are some headlines from around your world. Have a great day and stay in touch…
FDA Concludes Silicone Breast Implants Are Mostly Safe (Associated Press)
Merck KGgA Abandons Plan To Seek FDA Approval For MS Pill (Reuters)
FDA Panel Votes Against Recommending Novartis Gout Drug (Dow Jones)
High-Dose Statins May Cause Diabetes (MedPage Today)
EU Updates Tysabri Warning Label (Associated Press)
AstraZeneca Sells Tech Unit To Dentsply For $1.8 Billion (Reuters)
Merck Adds 70 Jobs At Irish Plant (Irish Independent)
Walgreen And Express Script Contract Unravels (Bloomberg News)
Shire Drug For Hereditary Angiodema Is Effective, FDA Says (Pharma Times)
Abbott And Biotest Ink Deal On Arthritis Drug (Reuters)
Abbott Positions Humira For Competition (Crain’s Chicago Business)
J&J Tries To Build Device Biz In Emerging Markets (The Star-Ledger of NJ)
EDITOR’S NOTE: Please check this post for updates throughout the morning
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Abbott Laboratories, AstraZeneca, Dentsply, Diabetes, Express Script, Gout, Humira, Ireland, JJ, jobs, Johnson & Johnson, Lipitor, Merck, Merck KgGA, MS, Multiple Sclerosis, Novartis, Pfizer, Shire Pharmaceuticals, Simvastatin, Statins, Walgreen, Zocor